



PRESS RELEASE:

June 25, 2025
Fuji Pharma Co., Ltd.

**Emergency contraceptive pill : LEVONORGESTREL tablet 1.5 mg "F"
Notice of Application for Marketing Approval as Switch OTC Drug**

Fuji Pharma Co., Ltd. announces that it has submitted an application for manufacturing and marketing approval of the emergency contraceptive pill LEVONORGESTREL tablet 1.5mg "F" as a switch over-the-counter (OTC) drug.

With regard to the switch OTC of emergency contraceptive pills, The Fifth Basic Plan for Gender Equality in 2020 stipulated that "Consider allowing access to emergency contraception, without a prescription, for women who have the possibility of unintended pregnancy". Subsequently, in 2021, the Evaluation and Review Committee began to study the switch to OTC, and from 2023, As part of a government specially approved clinical research, Trial sales of emergency contraceptive pill (morning-after pill) have begun at selected pharmacies.

The emergency contraceptive LEVONORGESTREL tablet 1.5mg "F", which we sell as an ethical drug, has a domestic market share of approximately 90%. In response to social demands for improved access to emergency contraceptive pills and enhanced women's well-being, rather than solely for ethical drugs, we submitted an application for manufacturing and marketing approval as an OTC drug in October 2024. The specific timing of approval has not yet been determined at this time, but we will monitor developments closely and promptly announce any updates.

For further information, contact

Fuji Pharma Co., Ltd.

Corporate Communication Section, Corporate Planning Department, Corporate Strategy Division

fsks@fujipharma.jp